Literature DB >> 21902528

APTIMA® Trichomonas vaginalis, a transcription-mediated amplification assay for detection of Trichomonas vaginalis in urogenital specimens.

Kimberle Chapin1, Sarah Andrea.   

Abstract

The APTIMA(®) Trichomonas vaginalis (APTIMA TV; Gen-Probe Inc.) assay is the only amplification-based assay for T. vaginalis (TV) currently cleared by the US FDA. The assay was cleared in April 2011. APTIMA TV utilizes target capture specimen processing, transcription-mediated amplification and chemiluminescent probe hybridization for the qualitative detection of TV ribosomal RNA. The assay is used for the screening/diagnosis of trichomoniasis in women. Specimen types that can be used include physician-collected endocervical swabs, vaginal swabs, endocervical specimens collected in PreservCyt(®) (Thin Prep, Hologic Incorporated, MA, USA) solution and female urine specimens. The APTIMA TV assay has shown superior performance in side-by-side comparisons with other diagnostic methods in all patient populations and specimen types tested. Clinical sensitivity and specificity are >95 and 98%, respectively. The APTIMA TV assay fills a significant void in sexually transmitted infection diagnostics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21902528     DOI: 10.1586/erm.11.53

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  8 in total

1.  Response to "Implications of Trichomonas vaginalis nucleic acid amplification testing on medical training and practice".

Authors:  C C Ginocchio; K Chapin; J S Smith; J Snook; C S Hill; J Aslanzadeh; C A Gaydos
Journal:  J Clin Microbiol       Date:  2013-05       Impact factor: 5.948

2.  Clinical evidence for the role of Trichomonas vaginalis in regulation of secretory leukocyte protease inhibitor in the female genital tract.

Authors:  Jill S Huppert; Bin Huang; Chen Chen; Hassan Y Dawood; Raina N Fichorova
Journal:  J Infect Dis       Date:  2013-01-25       Impact factor: 5.226

3.  Sexually transmitted infection prevalence in a population seeking no-cost contraception.

Authors:  Colleen McNicholas; Jeffrey F Peipert; Ragini Maddipati; Tessa Madden; Jenifer E Allsworth; Gina M Secura
Journal:  Sex Transm Dis       Date:  2013-07       Impact factor: 2.830

Review 4.  Modern diagnosis of Trichomonas vaginalis infection.

Authors:  Marcia M Hobbs; Arlene C Seña
Journal:  Sex Transm Infect       Date:  2013-04-30       Impact factor: 3.519

Review 5.  Trichomonas vaginalis: pathogenicity and potential role in human reproductive failure.

Authors:  Ewelina Mielczarek; Joanna Blaszkowska
Journal:  Infection       Date:  2015-11-06       Impact factor: 3.553

6.  Prevalence and predictors of trichomonas infection in newly incarcerated women.

Authors:  Ank E Nijhawan; Kimberle C Chapin; Rachel Salloway; Sarah Andrea; Jessi Champion; Mary Roberts; Jennifer G Clarke
Journal:  Sex Transm Dis       Date:  2012-12       Impact factor: 2.830

7.  Comparison between Aptima Assays (Hologic) and the Allplex STI Essential Assay (Seegene) for the diagnosis of Sexually transmitted infections.

Authors:  Adolfo de Salazar; Beatriz Espadafor; Ana Fuentes-López; Antonio Barrientos-Durán; Luis Salvador; Marta Álvarez; Federico García
Journal:  PLoS One       Date:  2019-09-12       Impact factor: 3.240

8.  Neglected parasitic infections in the United States: trichomoniasis.

Authors:  W Evan Secor; Elissa Meites; Michelle C Starr; Kimberly A Workowski
Journal:  Am J Trop Med Hyg       Date:  2014-05       Impact factor: 2.345

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.